Literature DB >> 20039849

Timing of uveitis onset in oligoarticular juvenile idiopathic arthritis (JIA) is the main predictor of severe course uveitis.

Maria E Zannin1, Irene Buscain, Fabio Vittadello, Giorgia Martini, Maria Alessio, Jelka G Orsoni, Luciana Breda, Donato Rigante, Rolando Cimaz, Francesco Zulian.   

Abstract

PURPOSE: Aim of the present study was to validate a statistical model to predict a severe course of anterior uveitis (AU) in patients with juvenile idiopathic arthritis (JIA).
METHODS: Consecutive patients with newly diagnosed uveitis have been followed for at least 1 year with a standardized protocol. For each patient, demographic, clinical and laboratory characteristics, including time interval between arthritis and uveitis onset, α(2)-globulins level at arthritis onset, number of uveitis relapses/year, ocular complications and therapy and visual acuity, have reported. The validation procedure included the assessment of sensitivity, specificity and efficiency of previously published statistical model (Zulian et al. J Rheumatol 2002; 29: 2446-2453) in a new inception cohort of patients during a short length follow-up.
RESULTS: Sixty patients with JIA, followed at 14 paediatric rheumatology-ophthalmology centres in Italy, entered the study. The mean age at arthritis onset was 4.4 years (range 1.2-15.8 years), and the mean interval time between arthritis and uveitis onset was 1.8 years (range: 0.0-14.2 years). After the first AU, patients, followed for a mean of 3.2 years, had a mean of 2.9 uveitis relapses. Twenty-two patients (36.7%) presented at least one complication. Using a probability cut-off value = 0.7, the statistical model revealed 80% sensitivity, 58% specificity and 65% efficiency.
CONCLUSION: The time interval between arthritis and uveitis onset resulted as the main predictor of severe course uveitis in JIA. The statistical model was able to predict the development of a severe course in 8 of 10 patients.
© 2009 The Authors. Journal compilation © 2009 Acta Ophthalmol.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20039849     DOI: 10.1111/j.1755-3768.2009.01815.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  10 in total

Review 1.  The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis.

Authors:  Melissa A Lerman; C Egla Rabinovich
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

Review 2.  Uveitis associated with juvenile idiopathic arthritis.

Authors:  Ethan S Sen; Andrew D Dick; Athimalaipet V Ramanan
Journal:  Nat Rev Rheumatol       Date:  2015-03-31       Impact factor: 20.543

3.  2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.

Authors:  Sheila T Angeles-Han; Sarah Ringold; Timothy Beukelman; Daniel Lovell; Carlos A Cuello; Mara L Becker; Robert A Colbert; Brian M Feldman; Gary N Holland; Polly J Ferguson; Harry Gewanter; Jaime Guzman; Jennifer Horonjeff; Peter A Nigrovic; Michael J Ombrello; Murray H Passo; Matthew L Stoll; C Egla Rabinovich; H Nida Sen; Rayfel Schneider; Olha Halyabar; Kimberly Hays; Amit Aakash Shah; Nancy Sullivan; Ann Marie Szymanski; Marat Turgunbaev; Amy Turner; James Reston
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-04-25       Impact factor: 4.794

4.  2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.

Authors:  Sheila T Angeles-Han; Sarah Ringold; Timothy Beukelman; Daniel Lovell; Carlos A Cuello; Mara L Becker; Robert A Colbert; Brian M Feldman; Gary N Holland; Polly J Ferguson; Harry Gewanter; Jaime Guzman; Jennifer Horonjeff; Peter A Nigrovic; Michael J Ombrello; Murray H Passo; Matthew L Stoll; C Egla Rabinovich; H Nida Sen; Rayfel Schneider; Olha Halyabar; Kimberly Hays; Amit Aakash Shah; Nancy Sullivan; Ann Marie Szymanski; Marat Turgunbaev; Amy Turner; James Reston
Journal:  Arthritis Rheumatol       Date:  2019-04-25       Impact factor: 10.995

5.  Development of a Nationally Agreed Core Clinical Dataset for Childhood Onset Uveitis.

Authors:  Ameenat Lola Solebo; Salomey Kellett; Jugnoo Rahi; Reshma Pattani; Clive Edelsten; Andrew D Dick; Alastair Denniston
Journal:  Front Pediatr       Date:  2022-06-21       Impact factor: 3.569

6.  Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis.

Authors:  Courtney McCracken; Steven Yeh; Kirsten Jenkins; Curtis Travers; Daneka Stryker; Steven Tommasello; Kelly A Rouster-Stevens; Scott R Lambert; Sampath Prahalad; Carolyn Drews-Botsch; Sheila T Angeles-Han
Journal:  Eye (Lond)       Date:  2018-11-28       Impact factor: 3.775

7.  Adalimumab for juvenile idiopathic arthritis-associated uveitis.

Authors:  Adriano Magli; Raimondo Forte; Pasqualina Navarro; Giustina Russo; Francesca Orlando; Loredana Latanza; Maria Alessio
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-01       Impact factor: 3.117

Review 8.  Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.

Authors:  Merih Oray; İlknur Tuğal-Tutkun
Journal:  Turk J Ophthalmol       Date:  2016-04-05

9.  Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative.

Authors:  Tamas Constantin; Ivan Foeldvari; Jordi Anton; Joke de Boer; Severine Czitrom-Guillaume; Clive Edelsten; Raz Gepstein; Arnd Heiligenhaus; Clarissa A Pilkington; Gabriele Simonini; Yosef Uziel; Sebastian J Vastert; Nico M Wulffraat; Anne-Mieke Haasnoot; Karoline Walscheid; Annamária Pálinkás; Reshma Pattani; Zoltán Györgyi; Richárd Kozma; Victor Boom; Andrea Ponyi; Angelo Ravelli; Athimalaipet V Ramanan
Journal:  Ann Rheum Dis       Date:  2018-03-28       Impact factor: 19.103

Review 10.  Juvenile idiopathic arthritis-associated uveitis.

Authors:  Sarah L N Clarke; Ethan S Sen; Athimalaipet V Ramanan
Journal:  Pediatr Rheumatol Online J       Date:  2016-04-27       Impact factor: 3.054

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.